News

Teck Resources (TECK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AEP (AEP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Compare global reach and income potential for these two international ETFs.

Jabil (JBL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Idex (IEX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Caterpillar (CAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

It’s quoted all the time, but I can’t stand adjusted EBITDA: earnings before interest, taxes, depreciation, and amortization, with management often adding back an even longer list of “one-time” expenses. The problem is that companies have considerable discretion over what gets excluded. Stock-based compensation, restructuring charges, litigation costs, acquisition expenses, and other recurring items can ... This Free Cash Flow ETF is Quietly Outperforming Vanguard’s S&P 500 in 2026

GE's commercial aerospace business is fueling growth with surging engine orders, strong services demand and major manufacturing investments for 2026.

CSTM's strong packaging, aerospace and automotive growth, plus a new $300M buyback, fuel a 56.5% YTD rally. What's next?

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

We just covered Avoid SpaceX and Buy These 11 Stocks Instead. Rocket Lab (NASDAQ:RKLB) ranks #10 (see Avoid SpaceX and Buy These 5 Stocks Instead). Number of Hedge Fund Investors: 43 Before SpaceX IPO’d, Rocket Lab (NASDAQ:RKLB) was one of the top space infrastructure plays. But when SpaceX went public at a $2 trillion valuation, […]

Gold regains momentum as cooling labor markets ease rate fears, putting gold ETFs back in focus.

(Bloomberg) -- Equities and event-driven strategies led hedge-fund gains in the first half of the year, after a brutal first quarter gave way to a broad recovery in recent months.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileWhy the Great American State Fair Looks So EmptyGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileMeta Is Planning a Cloud Business to Sell AI Computing PowerCastl

The 2026 rally in North Asian equities has been led by the two countries that fabricate the world’s most advanced semiconductors. The iShares MSCI South Korea ETF (NYSEARCA:EWY) is up 103% year to date, the iShares MSCI Taiwan ETF (NYSEARCA:EWT) is up 67%, and the broader iShares Asia 50 ETF (NASDAQ:AIA) has returned 43%. All ... 3 iShares ETFs to Buy Now as South Korea and Taiwan Soar Past 100% Gains in 2026

While these stocks operate in an industry known for razor-thin margins, software innovations are showing savvy investors how that could drastically change going forward.

U.K.’s BAE Systems, Italy’s Leonardo and Japan Aircraft Industrial Enhancement Co. secured a contract to develop a new stealth fighter jet.

FDA approved expanded use of CASGEVY for children as young as two years with sickle cell disease and transfusion-dependent beta thalassemia. The approval makes CASGEVY the first gene therapy of its kind available to this pediatric group in the U.S. Vertex Pharmaceuticals estimates that roughly 5,500 additional children in the U.S. may now be eligible for this one-time genetic treatment. Vertex Pharmaceuticals, traded as NasdaqGS:VRTX, now has FDA approval to offer CASGEVY to a much younger...

NOK's multi-year Orange Belgium deal expands its role in optical networking as demand rises from AI, cloud, 5G, streaming, gaming and remote work.

Delta (DAL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Samsung and major Korean firms deny formal Open USD ties, testing the new stablecoin's claimed 140-company alliance.

After losing some value lately, a hammer chart pattern has been formed for General Motors (GM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Big Short investor warns chip surge looks stretched

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

CoreWeave's 24% pullback has eased valuation concerns, but can explosive AI growth and a huge backlog outweigh rising competition and heavy spending?

Wall Street is drooling over Hewlett Packard Enterprise (NYSE:HPE) because the Juniper Networks deal detonated a 148.2% Networking revenue surge in the most recent quarter and management just yanked FY26 EPS guidance to $3.35 to $3.45 from a prior $2.25 to $2.45. But here’s what you should actually be watching. The HPE Story Is a ... Forget Hewlett Packard Enterprise: 1 Dividend-Rich Tech Giant to Buy Hand Over Fist on the Structural Pivot

SpaceX's stock has faced some selling pressure -- and it could get worse.

Coinbase (NASDAQ:COIN) and Strategy (NASDAQ:MSTR) both reported Q1 2026 results into a brutal crypto tape. Coinbase runs a fee-based crypto exchange with a growing subscription layer. Strategy is a leveraged bitcoin treasury wrapped around a shrinking software business. Same macro, very different machines. Exchange Fees Cushion Coinbase. Bitcoin Marks Break Strategy. Coinbase posted revenue of ... COIN Vs. MSTR: Buy Coinbase for Pure Exchange Fees and Structural Infrastructure Moats

After a 89% year-to-date rally that has taken shares from $143.89 to $271.95, Credo Technology Group (NASDAQ: CRDO) has become one of the most talked-about AI infrastructure plays on the market. Our 24/7 Wall St. price target for Credo is $248.61, implying -8.58% downside over the next 12 months. Our recommendation is hold, with a ... Price Prediction: Up 90% YTD, Will Credo’s Rally Continue?